June

/
/
June
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

– Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo – – Today’s LGS data follows…

FYCOMPA® (perampanel) Oral Suspension Now Available as an Option for Patients with Epilepsy Who May Have Difficulty Swallowing Tablets or Prefer Liquids

Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty…

ANNOUNCING New CURE Program: Post-Traumatic Epilepsy Initiative

In collaboration with the U.S. Department of Defense, CURE is excited to launch a NEW research program to support a collaborative, milestone-driven approach to advance…

Start typing and press Enter to search

Shopping Cart